AbstractBackgroundHHV‐8/Kaposi Sarcoma herpesvirus has been associated with a broad spectrum of diseases in solid organ transplant (SOT) recipients. Primary donor‐derived infection can be associated with severe and rapidly fatal non‐neoplastic disease, and diagnosis is made with high HHV‐8 DNAemia.MethodsWe carried out an international survey to investigate the current approach to HHV‐8 screening, and management in SOT since a protocol has not been established by international guidelines.ResultsA total of 51 transplant centers from 15 countries filled out the survey. HHV‐8‐associated diseases in SOT have been diagnosed during the previous 5 years in 67% of centers. Pretransplant serological screening is performed in 17 centers (33%), and posttransplant HHV‐8 nucleic acid testing (NAT) monitoring is performed in 21 centers (41%). Performing HHV‐8 NAT monitoring and serological screening were found associated with having diagnosed in the previous 5 years a non‐malignant HHV‐8‐associated disease.ConclusionsSerological pretransplant screening of donors and recipients and post‐transplant HHV‐8 NAT monitoring recommendations should be standardized. Even though serological assays are not optimal, they could contribute to increasing knowledge on epidemiology and management of HHV‐8‐associated diseases after SOT.